Evidence map›Paper›PMID 25490934›Full record

ArticleeLife2014

Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors.

Edward Greenfield, Erin Griner, Reproducibility Project: Cancer Biology

Open access · goldAbstract readComment
In one paragraph

Article in eLife, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Edward GreenfieldMonoclonal Antibody Core Facility, Dana-Farber Cancer Institute, Boston, United States.
Erin GrinerUniversity of Virginia, Charlottesville, United States.
Reproducibility Project: Cancer Biology
Boston University · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered Report describes the proposed replication plan of key experiments from "Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors" by Wilson and colleagues, published in Nature in 2012 (Wilson et al., 2012). The experiments that will be replicated are those reported in Figure 2B and C. In these experiments, Wilson and colleagues show that sensitivity to receptor tyrosine kinase (RTK) inhibitors can be bypassed by various ligands through reactivation of downstream signaling pathways (Figure 2A; Wilson et al., 2012), and that blocking the receptors for these bypassing ligands abrogates their ability to block sensitivity to the original RTK inhibitor (Figure 2C; Wilson et al., 2012). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by eLife.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsBreast NeoplasmsFemaleHepatocyte Growth FactorHumansIndolesMelanomaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesAntineoplastic AgentsHepatocyte Growth FactorIndolesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesbiochemistryhumanmethodologyreceptor tyrosine kinase inhibitorsReproducibility Project: Cancer Biologysignaling pathway reactivation

Identifiers

PMID25490934
PMCPMC4270159
OpenAlexW2018665153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.